Credit Suisse analyst Vamil Divan lowered his price target for Alkermes (ALKS) to $45 after updating company valuations in the small- to mid-cap Pharmaceuticals space. The analyst increased his discount rates for all his covered names in the sector saying a higher implied equity risk premium is appropriate in the current market environment. Divan also lowered his price target for Portola Pharmaceuticals (PTLA) to $41 from $59, for Adamas Pharmaceuticals (ADMS) to $30 from $37, for Aimmune Therapeutics (AIMT) to $35 from $44 and for Alder Biopharmaceuticals (ALDR) to $35 from $46. The analyst calls Portola as his top name heading into the early April data release for the phase 3 study of betrixaban in the acute medically ill population. He highlights Galapagos NV (GLPG) and Alkermes as being well-capitalized. Divan keeps an Outperform rating on Alkermes.